MAX Lab

Laboratory Investigation Report

Patient Name	Centre
Age/Gender	OP/IP No/UHID
MaxID/Lab ID	Collection Date/Time
Ref Doctor	Reporting Date/Time

Outsourced

SIN No:B2B2615379

Immunohistochemistry PDL1 22C3Dako(L)*

Immunohistochemistry (IHC) Number:
IHC-23707/22 (S-17965/21)

Specimen Type:
US guided trucut biopsy from right thigh lesion.

Histopathology (Biopsy) Opinion:
Moderately differentiated adenocarcinoma, metastasis to soft tissue.

Test Name
PD-L1 (Clone 22C3) Dako

Sample Adequacy:
Adequate tumor cells (>100 cells) are present: Yes

Immunohistochemistry (IHC) Result:

IHC Test /Marker	*Tumor Proportion Score (TPS) %*	*Combined Positive Score (CPS) %*
PD-L1 (Clone 22C3) Dako	0%	0%

Control:

Internal Control	Present
External Control	Positive

Interpretation
Pre-clinical studies suggest that positive PD-L1 immunohistochemistry in tumor cells may predict response to therapy with immune checkpoint inhibitors in certain clinical scenarios for Non-small cell lung carcinoma (NSCLC), cervical squamous cell carcinoma and endocervical adenocarcinoma, urothelial carcinoma, head and neck squamous cell carcinoma(HNSCC), gastric/gastro-esophageal junction adenocarcinoma and triple negative breast cancer (TNBC). This result should not be used as the sole factor in determining treatment, as other factors (for example, tumor mutation burder and microsatellite instability) have been also studied as predictive markers.

Test Performed at :910 - Max Hospital - Saket M S S H, Press Enclave Road, Mandir Marg, Saket, New Delhi, Delhi 110017
Booking Centre :2277 - Home Collection DNCR, Delhi
The authenticity of the report can be verified by scanning the Q R Code on top of the page

Max Lab Limited (A Wholly Owned Subsidiary of Max Healthcare Institute Ltd.)
Max Super Speciality Hospital, Saket (West Block), 1, Press Enclave Road, Saket, New Delhi - 110 017, Phone: +91-11-6611 5050
(CIN No.: U85100DL2021PLC381826)
Helpline No. 7982 100 200 www.maxlab.co.in feedback@maxlab.co.in

Patient Name	Centre
Age/Gender	OP/IP No/UHID
MaxID/Lab ID	Collection Date/Time
Ref Doctor	Reporting Date/Time

Outsourced

SIN No:B2B2615379

Scoring of PD-L1 is tumor site specific.
Staining can be present in both immune cell and tumor cell components.
Tumor cells: Any amount of partial or complete membrane staining is evaluated. Cytoplasmic staining is not included.
Immune cells: Both membrane or cytoplasmic staining of inflammatory cells (lymphocytes or macrophages) is counted.
Tumor proportion score (TPS) is the percentage of viable tumor cells showing partial or complete membrane staining relative to all viable tumor cells present in the sample.

$$TPS = \frac{\text{Number of PD-L1 positive tumor cells}}{\text{Total number of PD-L1 positive + PD-L1 negative tumor cells}} \times 100\ \%$$

Combined positive score (CPS) is the number of PD-L1 staining cells (tumor cells, lymphocytes and macrophages) divided by total number of viable tumor cells, multiplied by 100.

$$CPS = \frac{\text{Number of PD-L1 staining cells (tumor cells, lymphocytes, macrophages)}}{\text{Total number of viable tumor cells}} \times 100\ \%$$

Fixation
This test has been validated for non-decalcified paraffin embedded tissue specimens fixed in 10% neutral buffered formalin. This assay has not been validated on tissues subjected to the decalcification process and/ or use of alternative fixatives for bone/ bone marrow specimen or cell blocks.

Non small cell lung carcinoma
TPS divided into 3 groups:
TPS< 1%: no PD-L1 expression
TPS 1-49%: PD-L1 expression
TPS≥50%: high PD-L1 expression

Cervical carcinoma
CPS divided into 2 groups:
CPS<1: no PD-L1 expression
CPS≥1: PD-L1 expression

Urothelial carcinoma
CPS divided into 2 groups:
CPS<10: no PD-L1 expression
CPS≥10: PD-L1 expression

Head and neck squamous cell carcinoma (HNSCC)
CPS divided into 3 groups:
CPS<1: no PD-L1 expression
CPS≥1: PD-L1 expression
CPS≥20: PD-L1 expression

Patient Name	Centre
Age/Gender	OP/IP No/UHID
MaxID/Lab ID	Collection Date/Time
Ref Doctor	Reporting Date/Time

Outsourced

SIN No:B2B2615379

Gastric/ gastroesophageal junction adenocarcinoma
CPS divided into 2 groups:
CPS<1: no PD-L1 expression
CPS≥1: PD-L1 expression

Triple negative breast cancer (TNBC)
Urothelial carcinoma
CPS divided into 2 groups:
CPS<10: no PD-L1 expression
CPS≥10: PD-L1 expression

IHC markers / Additional information:
a) Detection System: *Optiview Amplification Kit with DAB – Ventana (IVD)*
b) Primary Antibodies: *Monoclonal Mouse Anti-Human PD-L1, Clone 22C3 Dako*

Kindly correlate with clinical findings

***** End Of Report *****

Dr. Sudhir B. Kulkarni M.D (Path)
Senior Consultant Histopathology

Test Performed at :910 - Max Hospital - Saket M S S H, Press Enclave Road, Mandir Marg, Saket, New Delhi, Delhi 110017
Booking Centre :2277 - Home Collection DNCR, Delhi
The authenticity of the report can be verified by scanning the Q R Code on top of the page